Document is current
Any future updates will be listed below
-
Authors
Forss, Anders https://orcid.org/0000-0002-1906-4982
Uchida, Amiko M.
Roelstraete, Bjorn
Ebrahimi, Fahim
Garber, John J.
Sundström, Johan
Ludvigsson, Jonas F.
-
Funding
Funding for this research was provided by:
Bengt Ihres Foundation (SLS-974469)
Svenska Läkaresällskapet (SLS-973638)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 5 February 2024
Accepted: 23 May 2024
First Online: 29 May 2024
Declarations
:
: This study and the ESPRESSO cohort were approved by the Regional Ethics Committee, Stockholm, Sweden (2014/1287-31/4 and 2018/972-32). Because this study was register-based, informed consent was waived.
: AF has served as a speaker and advisory board member for Janssen Corporation and Tillotts Pharma. AU has served as an advisory board member for Sanofi-Regeneron, Takeda and AstraZeneca. FE has served as an advisory board member for Boehringer Ingelheim. JJG has received research support from the American Partnership for Eosinophilic Disorders (APfED) and Takeda Pharmaceuticals. JS reports stock ownership in Anagram kommunikation AB and Symptoms Europe AB outside the submitted work. JFL has coordinated an unrelated study on behalf of the Swedish IBD quality register (SWIBREG). This study received funding from Janssen Corporation. JFL has also received financial support from MSD to develop a paper reviewing national healthcare registers in China. BR declares no conflicts of interest.
